Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MB-CART19.1 |
Synonyms | |
Therapy Description |
MB-CART19.1 consists of CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing 4-1-BBz, which potentially inhibits tumor growth (Blood (2021) 138 (Supplement 1): 3836; NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MB-CART19.1 | MBCART19.1|MB CART19.1|Autologous CD19 CAR-expressing CD4/CD8 pos T-cells | MB-CART19.1 consists of CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and containing 4-1-BBz, which potentially inhibits tumor growth (Blood (2021) 138 (Supplement 1): 3836; NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03853616 | Phase Ib/II | MB-CART19.1 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Recruiting | DEU | 0 |
NCT05705570 | Phase I | Cyclophosphamide + Fludarabine MB-CART19.1 | A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1) | Not yet recruiting | 1 |